Teva Pharmaceutical Industries annual net debt
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Net Debt Growth & History (TEVA)
Teva Pharmaceutical Industries's net debt was −$1.31B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.31B | −$198.0M | — |
| 2024 | 2024-12-31 | −$1.11B | −$8.0M | — |
| 2023 | 2023-12-31 | −$1.10B | −$877.0M | — |
| 2022 | 2022-12-31 | −$228.0M | −$39.0M | — |
| 2021 | 2021-12-31 | −$189.0M | −$1.82B | — |
| 2020 | 2020-12-31 | $1.63B | $675.0M | +70.90% |
| 2019 | 2019-12-31 | $952.0M | $518.0M | +119.35% |
| 2018 | 2018-12-31 | $434.0M | −$27.43B | −98.44% |
| 2017 | 2017-12-31 | $27.87B | −$3.68B | −11.68% |
| 2016 | 2016-12-31 | $31.55B | — | — |
| 2013 | 2013-12-31 | $10.16B | −$1.10B | −9.76% |
| 2012 | 2012-12-31 | $11.26B | $966.0M | +9.38% |
| 2011 | 2011-12-31 | $10.30B | $10.10B | +5127.41% |
| 2010 | 2010-12-31 | $197.0M | $716.0M | — |
| 2009 | 2009-12-31 | −$519.0M | −$3.39B | — |
| 2008 | 2008-12-31 | $2.87B | — | — |
Teva Pharmaceutical Industries quarterly net debt
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.13B | $2.53B | — |
| Q1 2026 | 2026-03-31 | −$849.0M | $139.0M | — |
| Q4 2025 | 2025-12-31 | −$1.31B | −$198.0M | — |
| Q3 2025 | 2025-09-30 | −$1.90B | −$1.45B | — |
| Q2 2025 | 2025-06-30 | −$1.40B | −$1.52B | — |
| Q1 2025 | 2025-03-31 | −$988.0M | −$1.35B | — |
| Q4 2024 | 2024-12-31 | −$1.11B | −$8.0M | — |
| Q3 2024 | 2024-09-30 | −$444.0M | $2.0M | — |
| Q2 2024 | 2024-06-30 | $117.0M | $468.0M | — |
| Q1 2024 | 2024-03-31 | $363.0M | $1.14B | — |
| Q4 2023 | 2023-12-31 | −$1.10B | −$877.0M | — |
| Q3 2023 | 2023-09-30 | −$446.0M | −$1.34B | — |
| Q2 2023 | 2023-06-30 | −$351.0M | −$383.0M | — |
| Q1 2023 | 2023-03-31 | −$775.0M | −$1.07B | — |
| Q4 2022 | 2022-12-31 | −$228.0M | −$39.0M | — |
| Q3 2022 | 2022-09-30 | $898.0M | −$191.0M | −17.54% |
| Q2 2022 | 2022-06-30 | $32.0M | −$1.51B | −97.92% |
| Q1 2022 | 2022-03-31 | $295.0M | −$1.10B | −78.85% |
| Q4 2021 | 2021-12-31 | −$189.0M | −$1.82B | — |
| Q3 2021 | 2021-09-30 | $1.09B | $338.0M | +45.01% |
| Q2 2021 | 2021-06-30 | $1.54B | $1.88B | — |
| Q1 2021 | 2021-03-31 | $1.40B | $1.16B | +488.61% |
| Q4 2020 | 2020-12-31 | $1.63B | $675.0M | +70.90% |
| Q3 2020 | 2020-09-30 | $751.0M | −$1.68B | −69.07% |
| Q2 2020 | 2020-06-30 | −$339.0M | −$1.52B | — |
| Q1 2020 | 2020-03-31 | $237.0M | −$1.14B | −82.84% |
| Q4 2019 | 2019-12-31 | $952.0M | $518.0M | +119.35% |
| Q3 2019 | 2019-09-30 | $2.43B | $1.63B | +204.26% |
| Q2 2019 | 2019-06-30 | $1.18B | $1.77B | — |
| Q1 2019 | 2019-03-31 | $1.38B | $1.50B | — |
| Q4 2018 | 2018-12-31 | $434.0M | −$27.43B | −98.44% |
| Q3 2018 | 2018-09-30 | $798.0M | −$30.50B | −97.45% |
| Q2 2018 | 2018-06-30 | −$589.0M | −$33.91B | — |
| Q1 2018 | 2018-03-31 | −$116.0M | −$32.06B | — |
| Q4 2017 | 2017-12-31 | $27.87B | −$3.68B | −11.68% |
| Q3 2017 | 2017-09-30 | $31.29B | −$329.0M | −1.04% |
| Q2 2017 | 2017-06-30 | $33.32B | $32.27B | +3067.49% |
| Q1 2017 | 2017-03-31 | $31.94B | $29.26B | +1091.42% |
| Q4 2016 | 2016-12-31 | $31.55B | $30.06B | +2021.79% |
| Q3 2016 | 2016-09-30 | $31.62B | $30.40B | +2491.97% |
| Q2 2016 | 2016-06-30 | $1.05B | −$902.0M | −46.16% |
| Q1 2016 | 2016-03-31 | $2.68B | $4.45B | — |
| As of Dec 31, 2015 | 2015-12-31 | $1.49B | −$4.90B | −76.71% |
| As of Sep 30, 2015 | 2015-09-30 | $1.22B | $861.0M | +239.83% |
| As of Jun 30, 2015 | 2015-06-30 | $1.95B | $855.0M | +77.80% |
| As of Mar 31, 2015 | 2015-03-31 | −$1.77B | −$2.42B | — |
| As of Dec 31, 2014 | 2014-12-31 | $6.39B | −$3.78B | −37.18% |
| Q3 2014 | 2014-09-30 | $359.0M | −$1.03B | −74.14% |
| Q2 2014 | 2014-06-30 | $1.10B | −$190.0M | −14.74% |
| Q1 2014 | 2014-03-31 | $651.0M | −$675.0M | −50.90% |
| Q4 2013 | 2013-12-31 | $10.16B | −$1.10B | −9.76% |
| Q3 2013 | 2013-09-30 | $1.39B | $2.25B | — |
| Q2 2013 | 2013-06-30 | $1.29B | $1.59B | — |
| Q1 2013 | 2013-03-31 | $1.33B | −$1.45B | −52.16% |
| Q4 2012 | 2012-12-31 | $11.26B | $966.0M | +9.38% |
| Q3 2012 | 2012-09-30 | −$861.0M | −$3.06B | — |
| Q2 2012 | 2012-06-30 | −$299.0M | −$1.09B | — |
| Q1 2012 | 2012-03-31 | $2.77B | $2.15B | +347.10% |
| Q4 2011 | 2011-12-31 | $10.30B | $10.10B | +5127.41% |
| Q3 2011 | 2011-09-30 | $2.20B | $2.04B | +1318.06% |
| Q2 2011 | 2011-06-30 | $788.0M | $3.67B | — |
| Q1 2011 | 2011-03-31 | $620.0M | $955.0M | — |
| Q4 2010 | 2010-12-31 | $197.0M | $716.0M | — |
| Q3 2010 | 2010-09-30 | $155.0M | −$555.0M | −78.17% |
| Q2 2010 | 2010-06-30 | −$2.89B | −$4.01B | — |
| Q1 2010 | 2010-03-31 | −$335.0M | −$2.55B | — |
| Q4 2009 | 2009-12-31 | −$519.0M | −$3.39B | — |
| Q3 2009 | 2009-09-30 | $710.0M | — | — |
| Q2 2009 | 2009-06-30 | $1.13B | — | — |
| Q1 2009 | 2009-03-31 | $2.21B | — | — |
| Q4 2008 | 2008-12-31 | $2.87B | — | — |
Teva Pharmaceutical Industries net debt trends
Over the last five fiscal years, Teva Pharmaceutical Industries's net debt decreased from $1.63B to −$1.31B, a change of −$2.94B. The latest reported quarter, Q2 2026, shows $1.13B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗